Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modified Post-Transplant Cyclophosphamide Combined With DCAG as a Bridge Followed by Busulfan, Fludarabine and Melphalan Based Conditioning Regimen for Children With Juvenile Myelomonocytic Leukemia

NCT03687463 is registered in ClinicalTrials.gov with Capital Research Institute of Pediatrics as lead sponsor.

NCT NCT03687463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03687463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modified Post-Transplant Cyclophosphamide Combined With DCAG as a Bridge Followed by Busulfan, Fludarabine and Melphalan Based Conditioning Regimen for Children With Juvenile Myelomonocytic Leukemia
Lead sponsor
Capital Research Institute of Pediatrics
Phase
Observational
Overall status
Unknown status
Start date
April 10, 2015
Completion date
April 10, 2020
Enrollment
6 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic system--cancer